186 related articles for article (PubMed ID: 33542075)
1. Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome.
Otvos B; Alban TJ; Grabowski MM; Bayik D; Mulkearns-Hubert EE; Radivoyevitch T; Rabljenovic A; Johnson S; Androjna C; Mohammadi AM; Barnett GH; Ahluwalia MS; Vogelbaum MA; Fecci PE; Lathia JD
Clin Cancer Res; 2021 Apr; 27(7):2038-2049. PubMed ID: 33542075
[TBL] [Abstract][Full Text] [Related]
2. Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma.
Voth BL; Pelargos PE; Barnette NE; Bhatt NS; Chen CHJ; Lagman C; Chung LK; Nguyen T; Sheppard JP; Romiyo P; Mareninov S; Kickhoefer VA; Yong WH; Rome LH; Yang I
J Neurooncol; 2020 May; 147(3):599-605. PubMed ID: 32274629
[TBL] [Abstract][Full Text] [Related]
3. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.
Khalsa JK; Cheng N; Keegan J; Chaudry A; Driver J; Bi WL; Lederer J; Shah K
Nat Commun; 2020 Aug; 11(1):3912. PubMed ID: 32764562
[TBL] [Abstract][Full Text] [Related]
4. Malignant Glioma Therapy by Vaccination with Irradiated C6 Cell-Derived Microvesicles Promotes an Antitumoral Immune Response.
Pineda B; Sánchez García FJ; Olascoaga NK; Pérez de la Cruz V; Salazar A; Moreno-Jiménez S; Hernández Pedro N; Márquez-Navarro A; Ortiz Plata A; Sotelo J
Mol Ther; 2019 Sep; 27(9):1612-1620. PubMed ID: 31204210
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
7. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
[TBL] [Abstract][Full Text] [Related]
8. Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.
Ayasoufi K; Pfaller CK; Evgin L; Khadka RH; Tritz ZP; Goddery EN; Fain CE; Yokanovich LT; Himes BT; Jin F; Zheng J; Schuelke MR; Hansen MJ; Tung W; Parney IF; Pease LR; Vile RG; Johnson AJ
Brain; 2020 Dec; 143(12):3629-3652. PubMed ID: 33253355
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
10. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
Bryant NL; Suarez-Cuervo C; Gillespie GY; Markert JM; Nabors LB; Meleth S; Lopez RD; Lamb LS
Neuro Oncol; 2009 Aug; 11(4):357-67. PubMed ID: 19211933
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
[TBL] [Abstract][Full Text] [Related]
12. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
[TBL] [Abstract][Full Text] [Related]
13. Effect of radiochemotherapy on peripheral immune response in glioblastoma.
Hampe L; Daumoine S; Limagne E; Roussot N; Borsotti F; Vincent J; Ilie S; Truntzer C; Ghiringhelli F; Thibaudin M
Cancer Immunol Immunother; 2024 May; 73(7):133. PubMed ID: 38753169
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
16. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
[TBL] [Abstract][Full Text] [Related]
17. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
[No Abstract] [Full Text] [Related]
19. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
20. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
